References
- Read NW, Sugden K. (1988). Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms. Crit Rev Ther Drug Carrier Syst, 4:221–263.
- Vishwanathan S. (2005). The latest in POP (tablet) technology. In Pharmaceutical Formulation & Quality, Vol. 7, pp. 32–34.
- Singh BN. (1999). Effects of food on clinical pharmacokinetics. Clin Pharmacokinet, 37:213–255.
- Fleisher D, Li C, Zhou Y, Pao LH, Karim A. (1999). Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet, 36:233–254.
- CDER. (2002). Guidance for Industry: Food–Effect Bioavailability and Fed Bioequivalence Studies, FDA, Vol. 2004–2005.
- Welling PG. (1984). Interactions affecting drug absorption. Clin Pharmacokinet, 9:404–434.
- Marasanapalle VP, Crison JR, Ma J, Li X, Jasti BR. (2009). Investigation of some factors contributing to negative food effects. Biopharm Drug Dispos, 30:71–80.
- Midha KK, McKay G, Rawson MJ, Korchinski ED, Hubbard JW. (2001). Effects of food on the pharmacokinetics of methylphenidate. Pharm Res, 18:1185–1189.
- Drabant S, Nemes KB, Horváth V, Tolokán A, Grézal G, Anttila M et al. (2004). Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers. Eur J Pharm Biopharm, 58:689–695.
- Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 46:75–87.
- Crauste-Manciet S, Decroix M, Farinotti R, Chaumeil J. (1997). Cefpodoxime-proxetil hydrolysis and food effects in the intestinal lumen before absorption: in vitro comparison of rabbit and human material. Int j Pharm, 157:153–161.
- McLean AJ, McNamara PJ, duSouich P, Gibaldi M, Lalka D. (1978). Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther, 24:5–10.
- Daneshmend TK, Roberts CJ. (1982). The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: A study with labetalol. Br J Clin Pharmacol, 14:73–78.
- Melander A. (1978). Influence of food on the bioavailability of drugs. Clin Pharmacokinet, 3:337–351.
- Williams L, Hill DP Jr, Davis JA, Lowenthal DT. (1996). The influence of food on the absorption and metabolism of drugs: An update. Eur J Drug Metab Pharmacokinet, 21:201–211.
- Melander A, Danielson K, Scherstén B, Wåhlin E. (1977). Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther, 22:108–112.
- Liedholm H, Melander A. (1986). Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther, 40:29–36.
- Axelson JE, Chan GL, Kirsten EB, Mason WD, Lanman RC, Kerr CR. (1987). Food increases the bioavailability of propafenone. Br J Clin Pharmacol, 23:735–741.
- Wilkinson GR. (1997). The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev, 27:129–159.
- Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
- Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res, 22:11–23.
- Wacher VJ, Salphati L, Benet LZ. (2001). Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev, 46:89–102.
- Carlisle KM, Halliwell M, Read AE, Wells PN. (1992). Estimation of total hepatic blood flow by duplex ultrasound. Gut, 33:92–97.
- Madsen JL, Søndergaard SB, Møller S. (2006). Meal-induced changes in splanchnic blood flow and oxygen uptake in middle-aged healthy humans. Scand J Gastroenterol, 41:87–92.
- Guyton AC, Hall JE. (1996). Textbook of Medical Physiology, Saunders Company, Philadelphia.
- Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, Lanc RA et al. (1983). Effect of food on hepatic blood flow: Implications in the “food effect” phenomenon. Clin Pharmacol Ther, 34:316–323.
- Lindenberg M, Kopp S, Dressman JB. (2004). Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm, 58:265–278.
- Bolger BM. (2007). In silico prediction of fraction absorbed. In Therapeutic Applications of Computational Biology and Chemistry. TABAC simulations plus, Inc., Cambridge, UK.
- Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA. (1983). Clinical pharmacology of propafenone. Circulation, 68:589–596.
- Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH. (1983). Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung, 33:763–770.
- Koytchev R, Alken RG, Mayer O, Smith I, Greenwood M. (1996). Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone–a novel antiarrhythmic agent. Eur J Clin Pharmacol, 50:315–319.
- NCSS. (2006). User’s Guide: Regression and curve fitting. NCSS, Kaysville, Utah.
- Roff D. (2002). Introduction to computer-intensive methods of data analysis in biology. Cambridge University Press, New York.
- Mora R. (2009). Vol. 2009. Department of Economics, Universidad Carlos III De Madrid.
- de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. (1990). Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther, 253:387–394.
- McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. (1995). Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut, 36:259–267.
- Peters WH, Kremers PG. (1989). Cytochromes P-450 in the intestinal mucosa of man. Biochem Pharmacol, 38:1535–1538.
- Murray GI, Barnes TS, Sewell HF, Ewen SW, Melvin WT, Burke MD. (1988). The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol, 25:465–475.
- Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. (1987). Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest, 80:1029–1036.
- Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. (1992). Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest, 90:1871–1878.
- Melander A, McLean A. (1983). Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet, 8:286–296.
- Welling PG. (1996). Effects of food on drug absorption. Annu Rev Nutr, 16:383–415.
- Ogiso T, Iwaki M, Tanino T, Kawafuchi R, Hata S. (1994). Effect of food on propranolol oral clearance and a possible mechanism of this food effect. Biol Pharm Bull, 17:112–116.
- Mäntylä R, Männistö P, Nykänen S, Koponen A, Lamminsivu U. (1983). Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol, 24:227–230.
- Ochs HR, Knüchel M. (1984). Pharmacokinetics and absolute bioavailability of diltiazem in humans. Klin Wochenschr, 62:303–306.
- Du Souich P, Lery N, Lery L, Varin F, Boucher S, Vezina M et al. (1990). Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. Biopharm Drug Dispos, 11:137–147.
- Levien TL, Baker DE. (2003). Cytochrome P450 drug interactions. In Pharmacist’s Letter, pp. 1–4.
- Gustafsson LL, Walker O, Alván G, Beermann B, Estevez F, Gleisner L et al. (1983). Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol, 15:471–479.
- Tulpule A, Krishnaswamy K. (1982). Effect of food on bioavailability of chloroquine. Eur J Clin Pharmacol, 23:271–273.
- Trenk D, Wagner F, Sachs W, Jähnchen E. (1989). Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. Eur J Clin Pharmacol, 37:313–316.
- Hardman JG, Limbird LE, Gilman AG. (Eds.) (2001). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, The McGraw-Hill Companies, Inc., New York, NY.
- Sandow N. (2003). Vol. 2004 RxList LLC. Electronic Source: www.rxlist.com
- Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH et al. (2006). Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol, 61:682–689.
- Drugs.com. (2010). Vol. 2010 Drugsite Trust.
- Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P et al. (2006). DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res, 34:D668–D672.
- Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D et al. (2008). DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res, 36:D901–D906.
- Yamazaki A, Kumagai Y, Fujita T, Hasunuma T, Yokota S, Maeda M et al. (2007). Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. J Clin Pharm Ther, 32:31–39.
- Debruyne D, Ryckelynck JP. (1993). Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet, 24:10–27.
- Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. (1994). Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol, 46:147–150.
- Hsyu PH, Giacomini KM. (1985). Stereoselective renal clearance of pindolol in humans. J Clin Invest, 76:1720–1726.
- Kiger JL, Lavene D, Guillaume MF, Guerret M, Longchampt J. (1976). The effect of food and clopamide on the absorption of pindolol in man. Int J Clin Pharmacol Biopharm, 13:228–232.
- Bergrem H, Grøttum P, Rugstad HE. (1983). Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur J Clin Pharmacol, 24:415–419.
- Tembo AV, Sakmar E, Hallmark MR, Weidler DJ, Wagner JG. (1976). Effect of food on the bioavailability of prednisone. J Clin Pharmacol, 16:620–624.
- Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. (1998). Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy, 18:1205–1211.
- Zent C, Smith P. (1995). Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis, 76:109–113.
- Ace LN, Jaffe JM, Kunka RL. (1983). Effect of food and an antacid on quinidine bioavailability. Biopharm Drug Dispos, 4:183–190.
- Kaul S, Christofalo B, Raymond RH, Stewart MB, Macleod CM. (1998). Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother, 42:2295–2298.
- Piscitelli SC, Kelly G, Walker RE, Kovacs J, Falloon J, Davey RT Jr et al. (1999). A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 43:647–650.
- Jackson SH, Wiffen JK, Johnston A, Peverel-Cooper CA. (1985). The relationship between clearance of theophylline and age within the adult age range. Eur J Clin Pharmacol, 29:177–179.
- Jonkman JH, van der Boon WJ, Balant LP, Le Cotonnec JY. (1985). Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. Eur J Clin Pharmacol, 28:225–227.
- Wilson TW, Firor WB, Johnson GE, Holmes GI, Tsianco MC, Huber PB et al. (1982). Timolol and propranolol: Bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther, 32:676–685.
- Jaeger A, Flesch F, Kopferschmitt J, Sauder P. (1991). Vol. 2009. International Programme on Chemical Safety (IPCS) and the Canadian Centre for Occupational Health and Safety (CCOHS).
- Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Mäenpää J, Pelkonen O. (2007). Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos, 35:1135–1141.